Publications by authors named "R Morese"

Article Synopsis
  • When patients with metastatic melanoma do not respond to PD-1 inhibitors, ipilimumab may be a viable second-line treatment option in the absence of clinical trials.
  • A study of 44 patients who received ipilimumab showed significant differences in overall survival based on genetic mutations (BRAF, NRAS) and the presence of brain metastases, with wildtype patients having the best survival rate.
  • The findings suggest that ipilimumab remains an effective therapy especially for those without brain metastases, highlighting the importance of genetic profile in treatment outcome.
View Article and Find Full Text PDF
Article Synopsis
  • Immunotherapy using anti-PD-1 antibodies has improved outcomes for advanced melanoma patients, but resistance to treatment is common.
  • This study analyzed the efficacy and safety of a weekly carboplatin plus paclitaxel (wCP) chemotherapy regimen in 30 patients who previously underwent anti-PD-1 treatment.
  • Key findings showed a median progression-free survival of 3.25 months and overall survival of 7.69 months, with notable factors influencing outcomes including LDH levels and tumor characteristics.
View Article and Find Full Text PDF

Background: Stage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit in the adjuvant setting for the delay of recurrence in stage III melanoma patients. Hyperprogression disease was observed as a possible adverse response to immunotherapy in the metastatic setting, suggesting that some patients could face additional risk of progression with ICIs, although no consensus was found for the correct definition of this event.

View Article and Find Full Text PDF

Introduction: This study aims to explore the relationship between cyberbullying involvement either as a perpetrator or a victim and emotional responses to virtual social exclusion and inclusion. Previous research has predominantly focused on the impacts of in-person bullying. Our study shifts this focus to the cyber realm.

View Article and Find Full Text PDF